Influx Healthtech Limited, has launched its initial public offering (IPO) on Jun 18, 2025, aiming to raise Rs 55.63 crore through fresh issue of 46.94 lakh equity shares aggregating to Rs 45.07 crores and offer for sale of 11.00 lakh shares aggregating to Rs 10.56 crores. Influx Healthtech IPO is set to close on Jun 20, 2025, with the shares expected to be listed on the NSE SME platform on Jun 25, 2025.
Influx Healthtech Limited Company Overview
Influx Healthtech is a Mumbai-based contract development and manufacturing organization (CDMO) specializing in third-party manufacturing and product development services for nutraceuticals, cosmetics, ayurvedic products, and veterinary feed supplements. The company operates three manufacturing facilities in Thane, Maharashtra, all certified with GMP, HACCP, ISO 22000, and Halal standards, and employs 165 permanent staff. Its product range includes tablets, gummies, jellies, skincare solutions, ayurvedic formulations, and homecare items. Influx Healthtech serves a diversified client base across India and has a presence in four continents. The company is currently expanding with plans to establish new manufacturing facilities focused on nutraceutical and veterinary products.
Influx Healthtech IPO Details
Influx Healthtech IPO is a bookbuilding IPO of Rs 55.63 crores. The issue is a combination of fresh issue of Rs 45.07 crores and Offer for Sales of Rs 10.56 crores. Rarever Financial Advisors Pvt. Ltd. is the book running lead manger of the Influx Healthtech Limited IPO, Maashitla Securities Private Limited is the Registrar for the issue. Market maker for Influx Healthtech IPO is R.K.Stock Holding Private Limited.
| Issue Type | Bookbuilding IPO |
| Face Value | Rs 10 per share |
| Issue Price | Rs 91 – Rs 96 per share |
| Lot Size | 1200 shares per lot |
| Issue Size | Rs 55.63 crore |
| Fresh Issue | Rs 45.07 crore |
| Offer for Sale (OFS) | Rs 10.56 crore |
| Listing at | NSE SME |
| Market Capitalization | Rs 222.24 cr |
| Book Running Lead Managers | Rarever Financial Advisors Pvt. Ltd. |
| Registrar | Maashitla Securities Private Limited |
| Market Maker | R.K.Stock Holding Private Limited |
Influx Healthtech IPO Timeline
Influx Healthtech Limited IPO opened on 18th Jun 2025 and Closes on 20th Jun 2025. Find Influx Healthtech IPO tentative dates below.
| IPO Open Date | 18-Jun-2025 (Wednesday) |
| IPO Close Date | 20-Jun-2025 (Friday) |
| Allotment | 23-Jun-2025 (Monday) |
| Initiation of Refunds | 24-Jun-2025 (Tuesday) |
| Demat Credit of Shares | 24-Jun-2025 (Tuesday) |
| Listing Date | 25-Jun-2025 (Wednesday) |
| Cut off time for UPI mandate confirmation | 20-Jun-2025 at 5PM |
Influx Healthtech IPO Lot Size
Investors can bid for a minimum of 1200 shares and in multiples thereof. The following table shows the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Minimum) | 1 | 1200 | Rs 1,15,200 |
| Retail (Maximum) | 1 | 1200 | Rs 1,15,200 |
| HNI (Minimum) | 2 | 2400 | Rs 2,30,400 |
Influx Healthtech IPO Objectives
The proceeds from the Influx Healthtech Limited IPO will be utilised for following purposes:
| Purpose | Amount (in Rs) | Percentage |
|---|---|---|
| Capital expenditure to set up manufacturing facility for Nutraceutical Division | 22.60 Crore | 47.00% |
| Capital expenditure to set up manufacturing facility for Veterinary Food Division | 11.59 Crore | 24.00% |
| Purchase of machineries for homecare and cosmetic division | 2.76 Crore | 5.75% |
| General corporate purpose |
Influx Healthtech IPO Financial Performance
Find Influx Healthtech Limited IPO last 3 years financial details below.
| Financials | 31-Mar-25 (Crores) | 31-Mar-24 (Crores) | 31-Mar-23 (Crores) |
|---|---|---|---|
| REVENUE | 104.99 | 100.10 | 76.07 |
| ASSETS | 70.30 | 41.10 | 28.30 |
| NET WORTH | 36.15 | 22.87 | 11.65 |
| TOTAL DEBT | 0.22 | 0.32 | 0.80 |
| PAT | 13.37 | 11.22 | 7.20 |
Influx Healthtech IPO Strengths and Risks
Strengths:
- Diversified portfolio across nutraceuticals, Ayurveda, and wellness products reduces sector-specific risks.
- Rigorous QA/QC processes, global certifications (ISO, FDA), and adherence to food safety standards ensure consistent high product quality.
- Formulation team develops safe, stable, and custom nutraceutical, cosmetic, and veterinary products for clients.
Risks:
- High reliance on the nutraceutical industry makes the company vulnerable to demand shifts or disruptions in that sector.
- Geographic concentration in Palghar, Maharashtra exposes the company to regional operational risks.
- Dependence on a few key customers (top 10 contributing ~47–50% of revenue) poses a risk, loss of any could significantly impact revenue and profitability.
- High dependence on top 10 suppliers (36–39%) without long-term contracts may disrupt operations if key relationships weaken or prices rise.
- Discrepancies and non-compliances in corporate records may lead to regulatory penalties, affecting the Company’s financial position.
Influx Healthtech IPO Grey Market Premium (GMP)
The grey market premium (GMP) for Influx Healthtech IPO on the final day of subscription (June 20, 2025) stood at Rs 38 per share. This suggests an expected listing price of around Rs 134, representing a potential gain of approximately 39% over the IPO’s upper price band of Rs 96 per share
Influx Healthtech Limited IPO Review: Apply
Disclaimer: This blog’s content is intended solely for informational and educational purpose only. Before making any investment decisions, it is recommended that investors consult with a certified financial advisor.